---
schema_version: "secwatch.filing_event.v1"
accession: "0001477449-23-000005"
form_type: "8-K"
ticker: "TDOC"
cik: "0001477449"
company_name: "Teladoc Health, Inc."
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:03:53.285276+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Teladoc Health Q2 revenue $652M (+10% YoY); adj EBITDA $72.2M beats outlook

## Summary
- Revenue $652.4M (+10% YoY); Integrated Care $360.1M (+5%), BetterHelp $292.4M (+18%).
- Net loss $65.2M ($0.40/share) vs $3.1B loss in Q2 2022 which included $3.03B goodwill impairment.
- Adjusted EBITDA $72.2M (+54% YoY), exceeding expectations; operating cash flow $101.2M.
- Q3 2023 guidance: revenue $650-$675M, adj EBITDA $72-$82M; full-year adj EBITDA $300-$325M.
- U.S. Integrated Care members guided at ~86 million for Q3 and full year 2023.

## SEC filing metadata
- accession: 0001477449-23-000005
- form_type: 8-K
- ticker: TDOC
- cik: 0001477449
- company_name: Teladoc Health, Inc.
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477449/000147744923000005/0001477449-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477449/000147744923000005/tdoc-20230725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477449-23-000005
- JSON: https://secwatch.observer/filing/0001477449-23-000005.json
- Plain text: https://secwatch.observer/filing/0001477449-23-000005.txt

## Key facts
- Earnings Releases
  Teladoc Health, Inc. reported Six Months Ended June 30, 2023 results: revenue $1,281.7 million, net income $134.4 million loss, EPS $0.82 loss per share.
  - Period: Six Months Ended June 30, 2023
  - Revenue: $1,281.7 million
  - Net income: $134.4 million loss
  - EPS: $0.82 loss per share
  - Result: reported results
  source text: quarter 2022. Adjusted gross margin (1) was 70.8% for second quarter 2023, compared to 69.2% for second quarter 2022. Six Months Ended June 30, 2023 Revenue increased 11% to $1,281.7 million from $1,157.7 million in the first half of 2022. Access fees revenue grew 12% to $1,126.5 million, and other revenue grew 5% to $155.1 million. U.S. revenue grew 9% to $1,103.4
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477449/000147744923000005/0001477449-23-000005-index.htm
- Earnings Releases
  Teladoc Health, Inc. reported Year ending December 31, 2023 results: revenue $2,600 - $2,675 million, EPS ($1.60) - ($1.25) loss per share. Guidance initiated.
  - Period: Year ending December 31, 2023
  - Revenue: $2,600 - $2,675 million
  - EPS: ($1.60) - ($1.25) loss per share
  - Guidance: initiated
  - Result: guidance update
  source text: For the year ending December 31, 2023, we expect: Full Year 2023 Outlook Range Revenue $2,600 - $2,675 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477449/000147744923000005/0001477449-23-000005-index.htm
- Earnings Releases
  Teladoc Health, Inc. reported Third quarter 2023 results: revenue $650 - $675 million, EPS ($0.50) - ($0.40) loss per share. Guidance initiated.
  - Period: Third quarter 2023
  - Revenue: $650 - $675 million
  - EPS: ($0.50) - ($0.40) loss per share
  - Guidance: initiated
  - Result: guidance update
  source text: For third quarter 2023, we expect: 3Q 2023 Outlook Range Revenue $650 - $675 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477449/000147744923000005/0001477449-23-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.